Randomized phase III study (ADMYRE) of plitidepsin in combination with dexamethasone vs. dexamethasone alone in patients with relapsed/refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Hematology"
DOI: 10.1007/s00277-019-03739-2
Abstract: The randomized phase III ADMYRE trial evaluated plitidepsin plus dexamethasone (DXM) versus DXM alone in patients with relapsed/refractory multiple myeloma after at least three but not more than six prior regimens, including at least bortezomib… read more here.
Keywords: relapsed refractory; refractory multiple; months arm; multiple myeloma ... See more keywords
A multicenter randomized phase III study for recurrent glioblastoma comparing bevacizumab alone with dose-dense temozolomide followed by bevacizumab: JCOG1308C.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.2046
Abstract: 2046 Background: Temozolomide (TMZ) is an alkylating agent commonly used as the standard therapy for newly diagnosed glioblastoma (GBM), with the DNA repair enzyme O 6 -methylguanine-DNA methyltransferase (MGMT) serving as a key prognostic and… read more here.
Keywords: tmz; gbm; months arm; mgmt ... See more keywords